Sun, 20 Aug 2017 12:00:00 EDT Easy Diabetes Treatment Study 1 Condition: Type 2 Diabetes Mellitus Interventions: Device: Standard of Care with EASY DSS; Other: Standard of Care without EASY DSS Sponsors: Läkarexpressen AB; Region Skane; Lund University Recruiting - verified August 2017
Sun, 20 Aug 2017 12:00:00 EDT Vitamin D in Diabetic Children Condition: Vitamin D Deficiency Intervention: Diagnostic Test: blood sample test Sponsor: Assiut University Recruiting - verified August 2017
Sun, 20 Aug 2017 12:00:00 EDT Islet Allotransplantation for Type 1 Diabetic Patients Condition: Type 1 Diabetic Intervention: Procedure: Allogeneic transplantation of intrahepatic islet Sponsor: Second Affiliated Hospital of Guangzhou Medical University Recruiting - verified August 2017
Sat, 19 Aug 2017 12:00:00 EDT FreeStyle Libre Flash Accuracy Study Condition: Diabetes Mellitus Intervention: Device: FreeStyle Libre Flash Glucose Monitoring System Sponsor: Abbott Diabetes Care Not yet recruiting - verified August 2017
Fri, 18 Aug 2017 12:00:00 EDT Effect of Viscous Soluble Fibres on Body Weight Conditions: Overweight and Obesity; T2DM (Type 2 Diabetes Mellitus); General Population Intervention: Dietary Supplement: Viscous Fibre Sponsor: St. Michael's Hospital, Toronto Active, not recruiting - verified August 2017
Thu, 17 Aug 2017 12:00:00 EDT Feasibility and Implementation of a Healthy Lifestyles Program Conditions: Health Behavior; Quality of Life; Chronic Disease; Health Promotion; Stress; Mental Health Wellness 1 Interventions: Behavioral: Health and wellness learning sessions; Behavioral: Brainstorming group sessions; Behavioral: Individual sessions with a multidisciplinary health team; Behavioral: Health goal development; Behavioral: Physical activity and nutrition journals Sponsor: McMaster University Not yet recruiting - verified August 2017
Thu, 17 Aug 2017 12:00:00 EDT Copeptin and NAFLD Condition: NAFLD Intervention: Behavioral: Recommended Daily Water Intake Sponsor: University of Colorado, Denver Not yet recruiting - verified August 2017
Wed, 16 Aug 2017 12:00:00 EDT Cue-Reward Learning and Weight Gain in Youth Conditions: Overweight; Obesity Intervention: Other: Functional MRI Sponsors: University of California, San Diego; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes of Health (NIH) Recruiting - verified August 2017
Wed, 16 Aug 2017 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Latest Top (10) News
Statement from FDA Commissioner Scott Gottlieb, M.D. – FDA is carefully evaluating prescription opioid medications approved to treat cough in children There’s perhaps no more important mandate that we have at the FDA than safeguarding the health and safety of children. For that reason, I believe it’s important that parents and health care providers have the best information available to inform the decisions they make about a child’s health. There are few more common decisions that parents and providers are asked to make than the question of how to appropriately treat a child’s cough and cold symptoms. Sometimes symptoms can be severe enough that prescription medication is needed, but some of these medications pose their own risks – especially for younger children – because they may contain opioids. Other times medication might not be necessary at all.
Thu, 17 Aug 2017 13:22:00 -0400 FDA warns of potential contamination in multiple brands of drugs, dietary supplements The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
Fri, 11 Aug 2017 15:34:00 -0400 FDA to expand public education campaign to focus on prevention of youth e-cigarette use Today, the U.S. Food and Drug Administration announced it would pursue a strategic, new public health education campaign aimed at discouraging the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) by kids. The agency plans to expand its “The Real Cost” public education campaign to include messaging to teens about the dangers of using these products this fall while developing a full-scale campaign to launch in 2018. These efforts are part of the agency’s new comprehensive plan for tobacco and nicotine regulation, as well as ongoing efforts to educate youth about, and protect them from, the dangers associated with using all tobacco products. It is the first time the FDA will be utilizing public health education to specifically target youth use of e-cigarettes or other ENDS.
Tue, 08 Aug 2017 10:00:00 -0400 Federal judge enters consent decree against outsourcing facility Isomeric Pharmacy Solutions U.S. District Judge Robert J. Shelby entered a consent decree of permanent injunction yesterday between the United States and Isomeric Pharmacy Solutions of Salt Lake City, Utah, two of the company’s co-owners, William O. Richardson and Rachael S. Cruz, and chief operating officer Jeffery D. Brown.
Fri, 04 Aug 2017 10:17:00 -0400 FDA approves Mavyret for Hepatitis C The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both.
Thu, 03 Aug 2017 15:06:00 -0400 FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine.
Thu, 03 Aug 2017 09:09:00 -0400 FDA approves treatment for chronic graft versus host disease The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy for the treatment of cGVHD.
Wed, 02 Aug 2017 11:30:00 -0400 FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.
Tue, 01 Aug 2017 11:10:00 -0400
Diabetes news from the American Diabetes Association
